Opus Genetics Reports Q2 Net Loss of $73.6M; Equity Turns Negative
Opus Genetics reported a significant increase in net loss to $73.6 million for the six months ended June 30, 2026, compared to $15.6 million in the prior year. Revenue from license and collaborations also declined to $2.9 million. The company's stockholders' equity turned negative, reaching $(13.0) million, while total liabilities substantially increased to $106.0 million. Despite these financial challenges, Opus Genetics secured new financing through a Note Purchase Agreement, with an initial $35.0 million funded, contributing to an increase in cash and cash equivalents to $88.8 million.
Key Highlights
- Net loss for six months ended June 30, 2026, was $73.6 million, up from $15.6 million in 2025.
- License and collaborations revenue decreased to $2.9 million for six months, from $7.3 million.
- Total stockholders' (deficit) equity turned negative at $(13.0) million as of June 30, 2026.
- Cash and cash equivalents increased to $88.8 million as of June 30, 2026.
- Total liabilities rose to $106.0 million as of June 30, 2026, from $34.9 million.
- Research and development expenses increased to $21.8 million for six months.
- Entered Note Purchase Agreement for up to $155.0 million, with $35.0 million funded.
Price Impact
More from IRD
Opus Genetics Presents Positive Clinical Data for OPGx-BEST1 and OPGx-LCA5 Gene Therapies
Opus Genetics Q2 Net Loss $8.1M; OPGx-BEST1 Data Sept 2026; Cash to 2029
Opus Genetics Completes Enrollment in OPGx-LCA5 Phase 3 Trial